----item----
version: 1
id: {0AAB70E6-0C64-4333-875A-5DAC29E86B1E}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/10/15/Elite Plans Opioid NDA Submission After Phase III Success
parent: {05EE13F4-80EE-4127-B996-2501E287FBE1}
name: Elite Plans Opioid NDA Submission After Phase III Success
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: c182c208-778b-4b1e-b0c4-a28eef265a7e

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 116

{07CF1C44-428A-445B-98D8-5EA9905BD7C5}|{D96D1CF9-9C1A-4F0C-8A5A-E8349BE8C5F6}|{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 57

Elite Plans Opioid NDA Submission After Phase III Success
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 57

Elite Plans Opioid NDA Submission After Phase III Success
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1942

<p>Elite Pharmaceuticals plans to submit a new drug application (NDA) to the US FDA by the end of this year based on positive Phase III results in the treatment of moderate to severe pain for ELI-200, an opioid-based pill designed with the company's proprietary abuse-deterrent technology (ART).</p><p>ELI-200 provided statistically significant pain relief compared with placebo in the treatment of post-surgical pain (p=0.001), meeting the primary endpoint in Elite's 163-patient Phase III pivotal study, and there were no serious adverse events or deaths linked to ELI-200. The Northvale, New Jersey-based company's lead opioid agonist candidate could be the fifth product with abuse-deterrent labeling, if the company follows the FDA's recent guidance. </p><p>Elite's ART platform combines an opioid agonist with the opioid antagonist naltrexone, which normally is used to treat alcohol and opioid dependence. ART enables naltrexone to move through the body unreleased, while the opioid agonist releases to provide pain relief, but if an ART-enabled pill is crushed or dissolved, naltrexone is released to block the opioid agonist's euphoric effects. </p><p>The FDA <a href="http://www.scripintelligence.com/home/FDA-guides-on-abuse-deterrent-opioids-generics-direction-pending-357633" target="_new">provided guidance in April</a> regarding the development of abuse-deterrent drugs that provide pain relief, but are formulated so that patients can't crush or dissolve then snort or inject the medicines. Only four approved, brand-name drugs have abuse-deterrent language in their labels.</p><p>Elite's NDA filing plans are on track, according to guidance the company provided earlier this year when it <a href="http://www.scripintelligence.com/home/marketdata/Pipeline-Watch---Pivotal-events-for-late-stage-and-marketed-drugs-5-11-June-2015-358919" target="_new">began enrolling patients</a> in the Phase III pivotal study.</p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 299

<p>Elite Pharmaceuticals plans to submit a new drug application (NDA) to the US FDA by the end of this year based on positive Phase III results in the treatment of moderate to severe pain for ELI-200, an opioid-based pill designed with the company's proprietary abuse-deterrent technology (ART).</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 57

Elite Plans Opioid NDA Submission After Phase III Success
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151015T180001
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151015T180001
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151015T180001
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC030110
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 57

Elite Plans Opioid NDA Submission After Phase III Success
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

200600165
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{B322F30F-1522-4633-91A4-A2EF3216848C}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

361068
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042509Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c182c208-778b-4b1e-b0c4-a28eef265a7e
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042509Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
